It's about more than blood sugar.
The report broadens the focus from managing hyperglycaemia to the whole picture of type 2 diabetes and long-term health.
Type 2 diabetes care is changing.
Five things worth knowing from the 2026 ADA/EASD consensus report , without having to read the whole clinical document.
Original evidenceManagement of Type 2 Diabetes, 2026 , a joint consensus report from the American Diabetes Association and European Association for the Study of Diabetes, published 2 October 2026.
5 things worth knowing
Heart, kidney, liver and weight goals matter.
Care should consider individualized weight management and protection of organs affected by diabetes-related conditions.
Some protective treatments may be considered earlier.
The report advocates earlier use , potentially from diagnosis in appropriate people , of SGLT2 inhibitors and/or GLP-1-based therapies for organ protection and long-term outcomes.
Daily life and psychological health are part of care.
Healthy eating, physical activity, sleep, avoiding tobacco and substance use, psychological support and weight management are described as fundamental aspects of care.
Care should be individualized , and equitable.
The report emphasizes person-centred decisions and says better outcomes depend on consistent, equitable implementation of strategies and therapies that already exist.
The 30-second version
Type 2 diabetes care is increasingly about much more than lowering glucose. The 2026 ADA/EASD report takes a broader approach: managing glucose while also considering weight, cardiovascular and kidney disease, heart failure, liver health, daily behaviours, psychological wellbeing and the individual person's priorities.
Why this matters
For someone outside diabetes care, the important shift is the frame. A diabetes consultation is not only about whether one laboratory number is “good” or “bad.” The report asks healthcare teams to think about the person's wider long-term health and to match treatment to their circumstances and risks.
MHH LENS
Access changes what recommendations can mean in real life.
A clinical guideline can describe what good care should look like, but access to medicines, diagnostics, specialist services and continuing care differs enormously between and within countries. MHH will keep that gap visible when explaining global recommendations.
What this doesn't tell us
- This is a consensus report for healthcare teams, not an individual treatment plan.
- Earlier use of a medicine does not mean that medicine is appropriate for everyone.
- The report's target audience is multidisciplinary healthcare teams providing care in the U.S. and Europe, so local guidelines, availability and health-system realities still matter.
- Treatment decisions should be made with a qualified healthcare professional who knows the person's medical history and circumstances.
GO TO THE EVIDENCE
Read the original report
Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. Published 2 October 2026.
Read the original report →MHH summaries are educational. They simplify selected findings and do not replace the full source or medical advice.